Welcome: Guest | Site Use Options | Register | Login |

Gamma Therapeutics Inc

Profile last edited on: 4/5/19
2611 SW Third Avenue Suite 280n
Portland, OR 97201
  (503) 222-2313
Business Identifier: Cardiovascular disease biomarker
Public Profile:
Gamma Therapeutics is a biotechnology venture developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry based upon a natural clotting protein in blood called Gamma Prime Fibrinogen - a natural occurring protein in human blood. It is a carrier protein for factor XIII, a thrombin binding site, forms clots that are resistant to fibrinolysis, and is strongly and significantly associated with cardiovascular disease. Early tests performed at the Framingham Heart Study, the Stockholm Coronary Artery Risk Factor Study and otherssee Proof of Concept pageindicated that if Gamma Prime Fibrinogen and Total Fibrinogen are elevated in the body, measured in the upper 25 percentile, there is a 3 fold to 7 fold odds of coronary heart disease. The Gamma Therapeutics product line includes its provisional-patented flagship product, GammaCoeur(tm), a cardiovascular disease risk diagnostic assay; GammaSeal(tm), a patent-pending, high strength post-surgical incision sealant, and; Gammarin(tm), a patented non-immunogenic blood anti-coagula

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Rapid Hemostatic Dressing for Hemorrhage Control
Venous Thromboembolism Risk Marker Assay

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920